Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

NIH 3OTHER 2INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Sarcoma 2CNS 2

Conditions

Carcinoma, Renal Cell 2Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × trebananib × Genitourinary × Clear all
NCT01664182 2022-06-07

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 13 charts
Genitourinary

Carcinoma, Renal Cell

NCT01553188 2019-03-05

AMG 386 and Abiraterone for Advanced Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
36 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT01548482 2015-10-06

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡